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Antibiotic resistance continues to pose a significant problem in the management of bacterial infections, despite advances in
antimicrobial chemotherapy and supportive care. Here, we suggest a simple, inexpensive, and easy-to-perform assay to screen
antimicrobial compounds from natural products or synthetic chemical libraries for their potential to work in tandem with the
available antibiotics against multiple drug-resistant bacteria. The aqueous extract of Juglans regia tree bark was tested against
representative multiple drug-resistant bacteria in the aforementioned assay to determine whether it potentiates the activity of
selected antibiotics. The aqueous extract of J. regia bark was added to Mueller-Hinton agar, followed by a lawn of multiple
drug-resistant bacteria, Salmonella typhi or enteropathogenic E. coli. Next, filter paper discs impregnated with different classes
of antibiotics were placed on the agar surface. Bacteria incubated with extract or antibiotics alone were used as controls.The results
showed a significant increase (>30%) in the zone of inhibition around the aztreonam, cefuroxime, and ampicillin discs compared
with bacteria incubated with the antibiotics/extract alone. In conclusion, our assay is able to detect either synergistic or additive
action of J. regia extract against multiple drug-resistant bacteria when tested with a range of antibiotics.
1. Introduction
Bacterial infections result in 17 million deaths worldwide
annually, mostly in children and the elderly [1]. The mor-
bidity and mortality associated with bacterial infections
have remained significant, despite advances in antimicrobial
chemotherapy. The situation has worsened with bacterial
resistance increasing to available antibiotics. From the 1930s
to 1960s, twenty classes of antibiotics were marketed but in
the last four decades only three new classes of antibiotics
have been introduced [1–5]. Today, multiple drug-resistant
bacteria such as methicillin-resistant Staphylococcus aureus
(MRSA), vancomycin-resistant enterococci (VRE), Acineto-
bacter baumannii, Klebsiella pneumonia, Escherichia coli, and
Pseudomonas aeruginosa pose a serious threat to human
and animal health. There is also the emergence of bacterial
pathogens with intrinsic resistance to antibiotics making
the available antibiotics obsolete [2]. A feasible approach to
counter such a crisis is to revive the use of available antibiotics
against multiple drug-resistant bacteria by improving their
efficacy. Here we suggest a simple, inexpensive and easy
assay to perform screening of antimicrobial compounds
from natural products [1] such as Juglans regia or synthetic
chemical libraries for their potential to work in tandem
with the available antibiotics against multiple drug-resistant
bacteria.Thebasis of this assay is that the extractmay enhance
the killing effect of synthetic antibiotics by overcoming the
resistant phenotype.
2. Materials and Methods
2.1. Bacterial Isolates. Two clinical isolates of Salmonella typhi
and enteropathogenic E. coli were used in this study. E. coli
isolate was derived from diarrheal stool sample and that of
Salmonella typhi was obtained from the blood cultures of a
typhoid patient. The clinical samples were plated on blood
agar plates. All the bacterial isolates were characterized by
colony morphology and biochemical testing and their iden-
tity confirmed by using API-20E system (bioMe´rieux). Both
isolates were preserved in glycerol stocks. For both bacteria,
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antibiotic evaluation test was performed on Mueller-Hinton
agar using Kirby-Bauer method as per Clinical Laboratory
Standards Institute [6, 7]. Salmonella typhi was considered
multiple drug resistant, if it exhibited growth on antibiotic
disks containing ampicillin 10𝜇g (breakpoint inhibition zone
for ampicillin for S. typhiwas considered 14mm), cefuroxime
30 𝜇g (breakpoint inhibition zone for cefuroxime for S. typhi
was considered 18mm), and aztreonam 10 𝜇g (breakpoint
inhibition zone was considered 24mm) as per EUCAST
guidelines. Similarly, E. coli was considered multiple drug
resistant, if it exhibited growth on antibiotic disks containing
ampicillin 10 𝜇g (breakpoint inhibition zone for ampicillin
for E. coli was considered 14mm), cefixime 5 𝜇g (breakpoint
inhibition zone was considered 17mm), and aztreonam 10𝜇g
(breakpoint inhibition zone was considered 24mm).
2.2. Juglans regia Extract. The aqueous extract of J. regia
(commonly known as Persian walnut or English walnut tree)
bark was prepared by taking 10 gram bark and mixing it in
100mL water overnight. Next day, the suspension was incu-
bated in boiling water bath for two minutes. Subsequently,
the mixture was cooled, centrifuged at 2500×g, and the
supernatant was filtered through 0.2 𝜇m filter. The filtrate
was evaporated using a refrigerated CentriVap Concentrator
(LabconcoCorp.) evaporator until dry and stored at 4∘Cuntil
further use.
2.3. Simple Plating Assay. The proposed assay utilizes the
modified version of the antibiotic disc diffusion assay
(“Kirby-Bauer” assay) [6, 7]. The Mueller-Hinton agar plates
were prepared containing aqueous extract of J. regia (final
concentration of extract was 0.625mg per mL of agar).
Next, 20mL of the overnight grown culture of multiple
drug-resistant bacteria, S. typhi and E. coli, was poured
on Mueller-Hinton agar containing J. regia extract plates
and left for 5min. Following this incubation, the excess
bacterial cultures were aspirated and plates were left in the
biosafety hood to dry. Next, filter paper discs impregnated
with different antibiotics (aztreonam, cefuroxime, ampicillin,
and cefixime) were placed on the agar surface and plates were
incubated at 37∘C overnight. Any change in the diameter
of the inhibition zone was measured to determine bacterial
sensitivity as per Clinical Laboratory Standards Institute [7].
Any increase in the diameter of the inhibition zone was
investigated to determine whether a specific antibiotic plus
J. regia extract has the potential to target the multiple drug-
resistant bacteria. For controls, S. typhi and E. coliwere plated
onMueller-Hinton agar plates containing extract but without
antibiotic discs. In some experiments, S. typhi and E. coliwere
plated onMueller-Hinton agar plates without extract but with
antibiotic discs.
3. Results
3.1. Aqueous Extract of J. regia Has Either a Synergistic Or
Additive Action against Multidrug-Resistant (MDR) Bacteria
When Tested with a Range of Antibiotics. When plated on
Mueller-Hinton agar plates containing J. regia extract but
without antibiotic discs, the growth of neither S. typhi nor
E. coli was affected. However, in the presence of antibiotics,
the results showed that the zone of inhibition for S. typhi
around the aztreonam antibiotic disc increased from 20mm
in Mueller-Hinton agar plates to 29mm in Mueller-Hinton
agar containing J. regia extract plates. Thus, the addition
of J. regia extract apparently renders once-resistant S. typhi
strain sensitive to aztreonam again (breakpoint inhibition
zone diameter of ≤24mmwas considered resistant) (Table 1).
Similarly, the zone of inhibition around the ampicillin antibi-
otic disc increased from 13mm in Mueller-Hinton agar
plates to 19mm in Mueller-Hinton agar containing J. regia
extract plates (Table 1). Thus, the addition of J. regia extract
apparently renders once-resistant S. typhi strain sensitive
to ampicillin again (breakpoint inhibition zone diameter of
≤14mm was considered resistant) (Table 1). However, J. regia
had limited effect on the resistance of S. typhi strain to
cefuroxime. The zone of inhibition around the cefuroxime
antibiotic disc increased from 12.5mm in Mueller-Hinton
agar plates to 18mm in Mueller-Hinton agar containing J.
regia extract plates (breakpoint inhibition zone diameter of
≤18mm was considered resistant) (Table 1).
The zone of inhibition for enteropathogenic E. coli
around the ampicillin antibiotic disc increased from 13mm
in Mueller-Hinton agar plates to 18mm containing J. regia
extract plates. Thus, the addition of J. regia extract renders
once-resistant E. coli strain sensitive to ampicillin again
(breakpoint inhibition zone diameter of ≤14mm was con-
sidered resistant) (Table 1). Similarly, the zone of inhibition
around the cefixime antibiotic disc increased from 16mm in
Mueller-Hinton agar plates to 22mm inMueller-Hinton agar
containing J. regia extract plates (Table 1). Thus, the addition
of J. regia extract renders once-resistant E. coli strain sensitive
to cefixime again (breakpoint inhibition zone diameter of
≤17mm was considered resistant) (Table 1). However, J. regia
extract had limited effect on the resistance of E. coli strain
to aztreonam. The zone of inhibition around the aztreonam
antibiotic disc increased from 14.5mm in Mueller-Hinton
agar plates to 21mm in Mueller-Hinton agar containing J.
regia extract plates (breakpoint inhibition zone diameter of
≤24mm was considered resistant) (Table 1). Both E. coli and
S. typhi lawns grew normally on plates added with J. regia’s
extract without antibiotics discs (data not shown).
4. Discussion
The basis of the proposed assay is that natural products
with potential antibacterial activity overcome the resistance
phenotype of multiple drug-resistant (MDR) bacteria and
render them susceptible to the available antibiotics. The
proposed assay has the potential to test the efficacy of
various antibiotics on a single plate in an easy-to-usemanner.
In addition, the proposed assay is cost-effective and can
be performed in a basic microbiology laboratory. Bacteria
employ a variety of strategies to develop resistance against a
single or group of antibiotics. These include drug-degrading
and -modifying enzymes, reduced membrane permeability
for drugs, expression of drug efflux pumps, overproduction
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Table 1: Juglans regia extract helped enhance the efficacy of
synthetic antibiotics and overcame the resistant phenotype. Data
are presented as the mean ± standard error of three independent
experiments.
Antibiotic
Zone of
inhibition,
mm (antibiotic
alone)
Zone of
inhibition, mm
(antibiotic +
Juglans regia
extract)
𝑃 value∗
Aztreonam (MDR
Salmonella typhi) 20 ± 3.4 29 ± 6.2 <0.01
Cefuroxime (MDR
Salmonella typhi) 12.5 ± 2.2 18 ± 2.5 <0.01
Ampicillin (MDR
Salmonella typhi) 13 ± 2.5 19 ± 1.8 <0.001
Aztreonam (MDR
enteropathogenic E. coli) 14.5 ± 3.5 21 ± 5.3 <0.01
Cefixime (MDR
enteropathogenic E. coli) 16 ± 5.1 22 ± 4.7 >0.05
Ampicillin (MDR
enteropathogenic E. coli) 13 ± 0.9 18 ± 3.1 >0.01
∗
𝑃 values were calculated using one-tailed paired 𝑡-test.
and alteration of drug targets, and bypassing the inhibitory
pathway [2].Thus, strategies (or use of natural products) that
can block the aforementioned drug resistance mechanisms
will allow the clinical use of currently available antibiotics.
This is not a novel concept and several studies have reported
the use of multiple compounds to produce synergistic or
additive effects against microbial pathogens [3, 6, 8, 9]. One
such example is coamoxiclav, a combination of amoxicillin
and clavulanic acid.This combination is also effective against
amoxicillin-resistant bacteria because clavulanic acid is an
inhibitor of 𝛽-lactamase, an enzyme which degrades 𝛽-
lactam drugs including amoxicillin. Other similar combina-
tions which are in clinical use include ampicillin/sulbactam
and piperacillin/tazobactam [10]. The findings reported here
suggest that J. regia extract can extend the clinical use of
available antibiotics.This is consistent with previous findings
which suggest that J. regia bark extract has either synergistic
or additive action against Gram-negative bacteria [11]. How-
ever, the mechanisms of action remain unknown, and future
studies are needed to identify the substance(s) present in the
J. regia extract responsible for the synergy with 𝛽-lactams.
Notably, J. regia is commonly used in some countries as a
toothbrush, and it has been suggested that brushing teeth
with this bark may improve oral hygiene, prevent plaque
and caries formation, and reduce the incidence of gingival
and periodontal infections [12]. Although there is no toxicity
data available for J. regia, recent findings suggest that J. regia
extract treatment (150mg/kg) resulted in protective restora-
tion of decreased antioxidants in a murine urotoxicity model
[13], albeit at considerable lower concentrations compared
with the present study.
It is instructive to point out that many molecular biosys-
tems and biomedical systems belong to themultilabel systems
in which each of the constituent molecules possesses one
or more than one function or feature and hence needs
one or more than one label to indicate its attribute(s), as
observed in recent antimicrobial peptides research [14]. Anti-
microbial peptides (AMPs) belong to the class of well-studied
multifunctional molecules. They are part of innate immune
mechanisms, found in almost all cellular organisms. Many
AMPs have been shown to possess a broad spectrum of
activities against viruses, bacteria, fungi, protists, parasites,
and surprisingly, even against tumor cells [15]. Mostly, AMPs
are cationic peptides and work through interfering with cell
membrane integrity or enter into the target cell and inhibit
vital cellular processes like DNA replication, transcription,
translation, and metabolic pathways [15]. Other important
features of AMPs include their low toxicity to mammalian
cells and slow rate of emergence of bacterial resistance
against them in comparisonwith the available antibiotics [16].
Recently, a number of powerful computational tools have
been developed to predict or design AMPs bearing one or
more activities [17, 18]. All of the above features have made
AMPs a promising candidate for future therapeutics [15].
However, as a first step, here we have tested the single-label
system. Many studies have indicated that cheminformatics
[19], mutagenesis [20], molecular docking [21, 22], predicting
drug-target interaction [23], and bioinformatics [24, 25] can
timely provide very useful information and insights for drug
development and hence are widely welcomed by the scientific
community. The present study attempted to develop a novel
method to screen potential antimicrobials using plate assay,
hoping that the new method can become a useful tool for
drug development.
Overall, our findings provide support that J. regia extract
enhances the efficacy of tested antibiotics against multiple
drug-resistant bacteria.The proposed assay can easily be used
to screen a wide range of natural products and compound
libraries. Our assay has an advantage of screening a pure
compound or natural product against five to eight different
antibiotics on the same plate. Because of its cost effectiveness
and simplicity, this assay could be used by labswhich have just
basicmicrobiology setup and limited funding and allow them
to contribute in the discovery of potential antimicrobials
that target drug-resistant pathways in multiple drug-resistant
bacteria, themechanisms of which will be explored in further
studies.
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